[Federal Register: November 15, 2004 (Volume 69, Number 219)]
[Notices]
[Page 65609-65610]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15no04-84]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Metal Chelators and Target-Moiety Complexes for Imaging
Martin W. Brechbiel and Thomas Clifford (NCI).
U.S. Provisional Application filed 23 Aug 2004 (DHHS Reference No. E-
317-2004).
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Available for licensing and commercial development are bifunctional
metal chelators, metal chelator-targeting moiety complexes, metal
chelator-targeting moiety-metal conjugates, kits, and methods of
preparing them. These chelators are useful in diagnosing and/or
treatment of cancer and thrombosis. The metal chelators may be used in
conventional and solid-phase synthetic methods to form targeting
moieties (e.g., peptides, and Starburst polyamidoamine dendrimers
(PAMAM), capable of conjugating diagnostic and/or therapeutic metals.
The formulae for two such chelators is shown below:
[GRAPHIC] [TIFF OMITTED] TN15NO04A.054
Anti-HIV Peptide Secreting Bacteria: Therapeutics and Methods of Use
Dean Hamer (NCI).
U.S. Provisional Application No. 60/604,051 filed 25 Aug 2004 (DHHS
Reference No. E-233-2004/0-US-01).
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Available for licensing and commercial development are genetically
[[Page 65610]]
engineered commensal bacteria compositions that secrete HIV infectivity
interfering peptides with the aid of co-expressed translocation
mediators such as HylB, HylD or tolC gene products. The bacteria can
be, for example, Escherichia coli and are preferably those that
colonize the gastrointestinal or genitourinary tracts. The secreted
anti-HIV peptide can be a functional inhibitory fragment from the C-
terminus of HIV, SHIV or SIV, or an inhibitory peptide derived from the
N-terminus receptor-binding domain of SIV gp41, HIV-1 gp41, or HIV-2
gp41. The secreted anti-HIV peptide can also be a peptide from the
allosteric domain of gp120, an extracellular loop of CCR5, an anti-CD4
immunoglobulin, a mimetic of CD4, an alpha-defensin or theta-defensin,
a CD38 fragment homologous to the V3 loop of gp120, polphemusin II (a
CXCR4 antagonist), a RANTES peptide that binds to CCR5 or an HIV
surface binding peptide such as cyanovirin.
Method of Assessing Ischemia in a Patient
Steven Warach, Lawrence Latour (NINDS).
U.S. Provisional Application No. 60/381,611 filed 17 Mar 2002 (DHHS
Reference No. E-082-2002/0-US-01); PCT Application No. PCT/US03/15368
filed 16 May 2003 (DHHS Reference No. E-082-2002/0-PCT-02).
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Hyperintense acute reperfusion marker (HARM) is well correlated
with reperfusion and is a precursor to or concomitant with reperfusion
injury. The inventors have developed a novel technique of assessing
injuries associated with ischemia, stroke, or reperfusion injury in a
patient by administering a contract agent to the patient, acquiring a
fluid-attenuated inversion-recovery (FLAIR) image, and observing the
presence or absence of HARM on the acquired image. The technique can
also be used to determine the effectiveness of a therapeutic protocol
for the treatment or prevention of reperfusion injury in a patient that
has previously suffered an ischemic event.
This research has been described, in part, in Latour et al.,
``Early Blood-Brain Barrier Disruption in Human Focal Brain Ischemia,''
Ann. Neurol. 2004 56:568-477.
Dated: November 4, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 04-25278 Filed 11-12-04; 8:45 am]
BILLING CODE 4140-01-P